Mechanisms of intrinsic tumor resistance to immunotherapy

John Rieth, Subree Subramanian

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

An increased understanding of the interactions between the immune system and tumors has opened the door to immunotherapy for cancer patients. Despite some success with checkpoint inhibitors including ipilimumab, pembrolizumab, and nivolumab, most cancer patients remain unresponsive to such immunotherapy, likely due to intrinsic tumor resistance. The mechanisms most likely involve reducing the quantity and/or quality of antitumor lymphocytes, which ultimately are driven by any number of developments: tumor mutations and adaptations, reduced neoantigen generation or expression, indoleamine 2,3-dioxygenase (IDO) overexpression, loss of phosphatase and tensin homologue (PTEN) expression, and overexpression of the Wnt–β-catenin pathway. Current work in immunotherapy continues to identify various tumor resistance mechanisms; future work is needed to develop adjuvant treatments that target those mechanisms, in order to improve the efficacy of immunotherapy and to expand its scope.

Original languageEnglish (US)
Article number1393
JournalInternational journal of molecular sciences
Volume19
Issue number5
DOIs
StatePublished - May 2 2018

Fingerprint

Immunotherapy
Tumors
tumors
Neoplasms
cancer
Indoleamine-Pyrrole 2,3,-Dioxygenase
immune systems
Catenins
phosphatases
Lymphocytes
Immune system
lymphocytes
Phosphatases
mutations
Phosphoric Monoester Hydrolases
inhibitors
Wnt Signaling Pathway
Immune System
Mutation
interactions

Keywords

  • Cancer immunotherapy
  • Oncogenes
  • Resistance
  • Signaling pathways

PubMed: MeSH publication types

  • Journal Article

Cite this

Mechanisms of intrinsic tumor resistance to immunotherapy. / Rieth, John; Subramanian, Subree.

In: International journal of molecular sciences, Vol. 19, No. 5, 1393, 02.05.2018.

Research output: Contribution to journalReview article

@article{eaf354ad36c3490cae99150c20a6ed6e,
title = "Mechanisms of intrinsic tumor resistance to immunotherapy",
abstract = "An increased understanding of the interactions between the immune system and tumors has opened the door to immunotherapy for cancer patients. Despite some success with checkpoint inhibitors including ipilimumab, pembrolizumab, and nivolumab, most cancer patients remain unresponsive to such immunotherapy, likely due to intrinsic tumor resistance. The mechanisms most likely involve reducing the quantity and/or quality of antitumor lymphocytes, which ultimately are driven by any number of developments: tumor mutations and adaptations, reduced neoantigen generation or expression, indoleamine 2,3-dioxygenase (IDO) overexpression, loss of phosphatase and tensin homologue (PTEN) expression, and overexpression of the Wnt–β-catenin pathway. Current work in immunotherapy continues to identify various tumor resistance mechanisms; future work is needed to develop adjuvant treatments that target those mechanisms, in order to improve the efficacy of immunotherapy and to expand its scope.",
keywords = "Cancer immunotherapy, Oncogenes, Resistance, Signaling pathways",
author = "John Rieth and Subree Subramanian",
year = "2018",
month = "5",
day = "2",
doi = "10.3390/s18051393",
language = "English (US)",
volume = "19",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - Mechanisms of intrinsic tumor resistance to immunotherapy

AU - Rieth, John

AU - Subramanian, Subree

PY - 2018/5/2

Y1 - 2018/5/2

N2 - An increased understanding of the interactions between the immune system and tumors has opened the door to immunotherapy for cancer patients. Despite some success with checkpoint inhibitors including ipilimumab, pembrolizumab, and nivolumab, most cancer patients remain unresponsive to such immunotherapy, likely due to intrinsic tumor resistance. The mechanisms most likely involve reducing the quantity and/or quality of antitumor lymphocytes, which ultimately are driven by any number of developments: tumor mutations and adaptations, reduced neoantigen generation or expression, indoleamine 2,3-dioxygenase (IDO) overexpression, loss of phosphatase and tensin homologue (PTEN) expression, and overexpression of the Wnt–β-catenin pathway. Current work in immunotherapy continues to identify various tumor resistance mechanisms; future work is needed to develop adjuvant treatments that target those mechanisms, in order to improve the efficacy of immunotherapy and to expand its scope.

AB - An increased understanding of the interactions between the immune system and tumors has opened the door to immunotherapy for cancer patients. Despite some success with checkpoint inhibitors including ipilimumab, pembrolizumab, and nivolumab, most cancer patients remain unresponsive to such immunotherapy, likely due to intrinsic tumor resistance. The mechanisms most likely involve reducing the quantity and/or quality of antitumor lymphocytes, which ultimately are driven by any number of developments: tumor mutations and adaptations, reduced neoantigen generation or expression, indoleamine 2,3-dioxygenase (IDO) overexpression, loss of phosphatase and tensin homologue (PTEN) expression, and overexpression of the Wnt–β-catenin pathway. Current work in immunotherapy continues to identify various tumor resistance mechanisms; future work is needed to develop adjuvant treatments that target those mechanisms, in order to improve the efficacy of immunotherapy and to expand its scope.

KW - Cancer immunotherapy

KW - Oncogenes

KW - Resistance

KW - Signaling pathways

UR - http://www.scopus.com/inward/record.url?scp=85046632145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046632145&partnerID=8YFLogxK

U2 - 10.3390/s18051393

DO - 10.3390/s18051393

M3 - Review article

VL - 19

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 5

M1 - 1393

ER -